发明名称 |
BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA |
摘要 |
Provided herein are the biomarkers for monitoring the treatment by immunomodulatory compounds. The use of biomarkers such as SPARC, p21, and cyclin D1 mRNA or protein levels as biomarkers to predict whether an immunomodulatory compound is likely to be successful in treating certain types of cancer, such as NHL, is also provided. Further, the expression of these genes or proteins can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with immunomodulatory compounds. |
申请公布号 |
EP2235535(B1) |
申请公布日期 |
2014.11.12 |
申请号 |
EP20080859508 |
申请日期 |
2008.12.05 |
申请人 |
CELGENE CORPORATION |
发明人 |
SCHAFER, PETER, H.;BARTLETT, JUSTIN, B.;ZHANG, LING-HUA |
分类号 |
G01N33/574;C12Q1/68 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|